CCM
ADVM

Cadian Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Cadian Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-11,387
Closed -$589K – 45
2016
Q1 		$589K Sell
11,387
-141,567
-93% -$7.9M 0.04% 56
2015
Q4 		$14.6M Buy
152,954
+4,785
+3% +$420K 0.52% 47
2015
Q3 		$12.2M Buy
148,169
+47,335
+47% +$6.05M 0.44% 56
2015
Q2 		$16.4M Buy
100,834
+67,500
+202% +$22.8M 0.48% 46
2015
Q1 		$13.5M Buy
33,334
+27,334
+456% +$11.6M 0.36% 49
2014
Q4 		$3.24M Buy
+6,000
New +$2.31M 0.08% 92

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Cadian Capital Management's ADVM Position: Q2 2016 in Review

Cadian Capital Management sold out of Adverum Biotechnologies (ADVM) in Q2 2016, closing a stake of 11,387 shares — an estimated $589K sold.

Cadian Capital Management first reported a position in ADVM in Q4 2014 and held it in 6 quarters. The position peaked at $16.4M in Q2 2015. 77 funds tracked by Wall St. Rank hold ADVM as of Q2 2016.

  • Cadian Capital Management reported no remaining Adverum Biotechnologies position as of Q2 2016 after selling out during the quarter.
  • Cadian Capital Management sold 11,387 Adverum Biotechnologies shares in Q2 2016, an estimated $589K.
  • Cadian Capital Management first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 6 quarters.
  • Cadian Capital Management's Adverum Biotechnologies position peaked at $16.4M in Q2 2015.
  • 77 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2016.

Based on Cadian Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.